Both in Biotechnology
Replimune Group vs Recursion Pharmaceuticals
Over the past year REPL returned +121.9% and RXRX returned −32.4%; their daily moves had a correlation of 0.10.
REPL +121.9% RXRX −32.4%Growth of $1, one year, split-adjusted
| Metric | REPL | RXRX |
|---|---|---|
| Price | $20.65 | $3.68 |
| Market cap | $1.96B | $2.20B |
| Today | +5.95% | −3.92% |
| 1 month | +57.0% | −23.0% |
| 6 months | +619.5% | +9.2% |
| Year to date | +112.4% | −10.0% |
| 1 year | — | −33.3% |
| Revenue growth (YoY) | — | +258.5% |
| Gross margin | — | 45.9% |
| Net margin | — | −641.6% |
| P/E (TTM) | — | — |
| Price / sales | — | 32.2× |
| Net cash | $183.7M | $538.0M |
| Dividend yield | — | — |
| Volatility (60d) | 77.7% | 95.4% |
| Short % of float | 29.6% | 37.5% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).